新検索ページはこちら
ログイン
お問い合わせ
（旧版）科学的根拠に基づく膵癌診療ガイドライン 2006年版
書誌情報
CQ1 診断法
CQ1-3 膵癌の診断法：ファーストステップは何か?
【引用文献】
| 1） | 真口宏介，小原 剛，丹野誠志，藤井常志，伊藤彰規，西野徳之，高橋邦幸，山野三紀．早期膵臓癌の診断; 超音波，腫瘍マーカー．外科 1995; 57: 256-261. |
| 2） | 日本膵臓学会膵癌登録委員会．膵癌全国登録調査報告．膵臓 2001; 16: 115-147. |
| 3） | Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 2004; 28: 263-267. |
| 4） | 江川新一，武田和憲，赤田昌典，阿部 永，横山忠明，元井冬彦，福山尚治，砂村眞琴，松野正紀．小膵癌の全国集計の解析．膵臓 2004: 19: 558-566. |
| 5） | Satake K, Chung YS, Yokomatsu H, Nakata B, Tanaka H, Sawada T, Nishiwaki H, Umeyama K. A clinical evaluation for various tumor markers for the diagnosis of pancreatic cancer. Int J Pancreatol 1990; 7: 25-36. |
| 6） | Nazli O, Bozdag AD, Tansung T, Kir R, Kaymak E. The diagnostic importance of CEA and CA19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterol 2000; 47: 1750-1752. |
| 7） | Kawa S, Tokoo M, Hasebe O, Hayashi K, Imai H, Oguchi H, Kiyosawa K, Furuta S, Homma T. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994; 70: 481-486. |
| 8） | Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9. Int J Pancreatol 1994; 15: 171-177. |
| 9） | 田所洋行，渡辺伸一郎，竹内 正．膵癌診断における尿中フコースの意義．膵臓 1995; 10: 374-380. |
| 10） | Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen（TPS）, a marker for differentiation between pancreatic carcinoma and chronic pancreaittis. A comparative study with CA 19-9. Cancer 2000; 89: 83-88. |
| 11） | Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. A prospective study of serum tumor markers carcinoembryonic antigen, carbohydrate antigen 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 1994; 69: 562-565. |
| 12） | Hayakawa T, Naruse S, Kitagawa M, Ishiguro H, Kondo T, Kurimoto K, Fukushima M, Takayama T, Horiguchi Y, Kuno N, Noda A, Furukawa T. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer form benig pancreatic diseases. Int J Pancreatol 1999; 25: 23-29. |
| 13） | Nakao A, Oshima K, Nomoto S, Takeda S, Kaneko T, Ichihara T, Kurokawa T, Nonami T, Takagi H. Clinical usefulness of CA19-9 in pancreatic carcinoma. Semin Surg Oncol 1998; 15: 15-22. |
| 14） | Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998; 45: 253-259. |
| 15） | Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997; 4: 551-556. |
| 16） | 増田英明，今村清子，酒井辰彦，四宮由美子，小松弘一，西山和男，土橋健，佐島敬清．施設検診発見膵癌の実態とその予後に関する検討．日消集検誌 1999; 37: 293-299. |
| 17） | 北川元二，成瀬 達，石黒 洋，水野伸匡，斉藤征夫．腹部超音波検診における膵癌発見の現状．日消集検誌 2003; 41: 25-29. |
| 18） | Tanaka S, Kitamura T, Yamamoto K, Fujikawa S, Imaoka T, Nishikawa S, Nakaizumi A, Uehara H, Ishikawa O, Ohigashi H. Evaluation of routine sonography for early detection of pancreatic cancer. Jpn J Clin Oncol 1996; 26: 422-427. |
| 19） | Tanaka S, Nakaizumi A, Ioka T, Oshikawa O, Uehara H, Nakao M, Yamamoto K, Ishikawa O, Ohigashi H, Kitamra T. Main pancreatic duct dilation: a sign of high risk for pancreatic cancer. Jpn J Clin Oncol 2002; 32: 407-411. |
| 20） | Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y, Xuezhi W. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutation and serum CA19-9 analysis. Pancreas 2002; 25: 336-341. |
| 21） | Uemura T, Hibi K, Kaneko T, Takeda S, Inoue S, Okochi O, Nagasaka T, Nakao A. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol 2004; 39: 56-60. |
| 22） | Suwa H, Ohshio G, Okada N, Wang Z, Fukumoto M, Imamura T, Imamura M. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 1997; 40: 647-653. |
